LILLE, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--It has come to the attention of Genfit, a leading biotech company listed on Alternext (NYSE Euronext - Paris), that an undisclosed group of so-called “well known scientific experts” have issued a press release, via a news wire, purporting to put into question the effectiveness of Genfit’s main clinical drug candidate GFT 505.
